Abstract: Studying posttranslational modifications classically relies on experimental strategies that oversimplify the complex biosynthetic machineries of living cells. Protein glycosylation contributes to essential biological processes, but correlating glycan structure, underlying protein and disease-relevant biosynthetic regulation is currently elusive. Here, we engineer living cells to tag glycans with editable chemical functionalities while providing information on biosynthesis, 5 physiological context and glycan fine structure. We introduce a non-natural substrate biosynthetic pathway and use engineered glycosyltransferases to incorporate chemically tagged sugars into the cell surface glycome of the living cell. We apply the strategy to a particularly redundant yet disease-relevant human glycosyltransferase family, the polypeptide N-acetylgalactosaminyl transferases. This approach bestows a gain-of-function modification on cells where the products 10 of individual glycosyltransferases can be selectively characterized or manipulated at will.
Main Text: Posttranslational modifications expand the structural diversity of proteins, but are notoriously difficult to study in living systems. Most modifications are refractory to direct genetic manipulation and require reductionist strategies such as in vitro systems or simplified cells.
Glycans are the prime example for this: the human glycome is constructed by the combinatorial 15 activity of more than 250 glycosyltransferases (GTs) with both hierarchical and competing activities. On the cell surface, glycans play a central role in modulating signal transduction, cellcell interactions and biophysical properties of the plasma membrane (1, 2) . Understanding and manipulating these processes should thus be possible by adorning specific glycans with editable chemical functionalities. In such a synthetic biology approach, individual GTs could be engineered 20 to accommodate a chemical functionality that is not found in native substrates and not accommodated by other GTs. This "bump-and-hole" tactic has been applied to a range of enzymes by us and others (3) (4) (5) (6) (7) (8) (9) , but application in the living cell is a substantial technical challenge: the nucleotide-based substrate analog must be delivered across the plasma membrane and the cell must stably express the correctly localized and folded mutant enzyme. Bump-and-hole engineering is particularly attractive to deconvolve GT families of multiple homologous isoenzymes: the complex interplay of these isoenzymes in the secretory pathway cannot be probed in sufficient detail in in vitro assays. 5 One of the largest GT families in the human genome is the polypeptide N-acetylgalacosaminyl (GalNAc) transferase family (GalNAc-T- 1…T-20) . Transferring GalNAc to Ser/Thr side chains, GalNAcTs initiate abundant O-linked glycosylation in the secretory pathway ( Fig. 1A) (10, 11) .
O-GalNAc glycosylation can differ based on cell type or activation stage, and clear disease phenotypes are associated with glycan aberration (12, 13) . Unsurprisingly, GalNAcT expression 10 is often associated with tumorigenesis, sometimes with opposite effects on different types of cancer (14, 15) . However, the absence of a glycosylation consensus sequence and the variability of glycan elaboration render O-GalNAc glycans challenging to study by mass spectrometry (MS) based glycoproteomics. Thus, the protein substrate specificity of each isoenzyme is poorly studied and largely built on data inferred from synthetic peptide libraries (16). So-called SimpleCells that 15 do not elaborate O-GalNAc glycans make glycoproteins that are easier to enrich and study by MS (17-20). Knock-outs of single GalNAcTs in the SimpleCell background have been profiled by glycosproteomics (18, 21) . Similarly, glycopeptides from non-SimpleCells with titratable GalNAcT knock-in have been enzymatically simplified to allow for enrichment and MS (22) .
These studies have revealed comprehensive glycoproteomics datasets, but suffer from loss of 20 glycan elaboration and laborious genome engineering required for targeted knock-in. Further, the activity of GalNAcT isoenzymes is both redundant and competitive, such that compensation and/or 4 shift of glycosylation sites occurs upon knock-out (21, 22) . A gain-of-function strategy to visualize the products of a particular GT on the living cell is currently elusive. Here, we equipped living cells with the ability to tag the protein substrates of individual GalNAcTs with chemical, editable functionalities. We made use of the fact that a double mutation ("DM", I253A/L310A double mutant in T-2, fig. 1B ) re-programmed GalNAcTs to accept alkynecontaining uridine diphosphate (UDP)-GalNAc analogs such as compounds 1-4 instead of the native substrate UDP-GalNAc ( Fig. 1B) (8) . We endowed living cells with the capacity to biosynthesize a UDP-GalNAc analog that was complementary to engineered DM-GalNAcTs.
Further, we showed that DM-GalNAcTs emulate wild type (WT) GalNAcTs with regard to 5 structure, localization and protein substrate specificity. This approach bestowed a bioorthogonal tag (23-27) on the protein substrates of distinct GalNAcT isoenzymes while conserving the complexity of glycan elaboration in the secretory pathway ( Fig. 1C ). Precision glycome engineering has widespread applications in biomarker discovery, GT profiling and targeted cell surface engineering.
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Structural basis for GalNAcT engineering
As bump-and-hole engineering of a GT family in living cells has no precedent, we first set out to understand the structural implications of this approach. All GalNAcTs are type II transmembrane proteins with luminal GT and lectin domains connected through a flexible linker (10, 11, 28) . We crystallized the luminal part of DM-T-2 in complex with the native ligands Mn 2+ , UDP, and the 15 substrate peptide EA2 (PTTDSTTPAPTTK) at 1.8 Å resolution. Comparison of DM-T-2 and WT-T-2 (PDB 2FFU) revealed complete conservation of both the three-dimensional enzyme architecture and bound ligand structure ( Fig. 2A, fig. S1 and Table S1) (29). In DM-T-2, the interdomain linker adopts an extended conformation previously found in the catalytically active WT enzyme (30, 31). The mutant A253 and A310 side chains in the DM enzyme are congruent 20 with the WT side chains I253 and L310, respectively ( Fig. 2B ). Two glycine residues, G308 and G309, are slightly shifted by 1.2 Å and 1.7 Å (Cα distances), respectively, likely to account for the changes elsewhere in the active site. DM-T-2 thus retains the native structural properties of the WT-GalNAcT enzyme. binding is completely conserved (Fig. S1B , C and table S1) (30). DM-T-2 indeed contains a hole that accommodates the alkyne side chain bump in UDP-GalNAc analog 1 (Fig. 2C ). The formation of additional van der Waals interactions between enzyme and substrate explain why the KM of DM-T-2 toward 1 is approximately ten-fold lower than the KM of WT-T-2 toward UDP-GalNAc (8) .
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To corroborate our structural interpretation that GalNAcT bump-and-hole engineering does not alter substrate peptide binding, we profiled the substrate specificities of two engineered GalNAcTs, DM-T-1 and DM-T-2 (8, (33) (34) (35) . A peptide library containing a single Thr residue with randomized neighboring residues was used in in vitro glycosylation experiments and analyzed 
DM-GalNAcTs glycosylate membrane proteins
We next sought to confirm that DM-GalNAcTs localize to the Golgi compartment and glycosylate alkyne chain led to substantial labeling, consistent with 4 being a substrate for WT-GalNAcTs (8, 26) . These results were confirmed using soluble GalNAcTs and a membrane fraction of nontransfected cells (Fig. S3E ). Importantly, profiling both enzyme activity and protein specificity of 20 single GalNAcT isoenzymes has been impossible to date even in cell lysates. We next targeted a
GalNAcT bump-and-hole platform in the living cell.
Biosynthesis of a bumped UDP-GalNAc analog
Among the insightful bump-and-hole studies that have probed various enzyme families, few have been performed in living cells due to the inability to deliver negatively charged substrates across the plasma membrane (5, 6, 9, 37) . GalNAc analogs have been fed to cells as membrane-permeable 5 per-acetylated precursors that are deprotected by esterases and converted to UDP-GalNAc analogs via the kinase GALK2 and the pyrophosphorylase AGX1 ( Fig. 4A) (26, 27, 38, 39) . By delivery of the corresponding protected GalNAc-1-phosphate analog, a GalNAc analog can bypass GALK2, such that only AGX1 is necessary for biosynthesis to the UDP-GalNAc analog. However, in accordance with previous findings (39) , bumped UDP-GalNAc analogs 1, 2 and 3 were not 10 biosynthesized from their sugar-1-phosphate precursors in the living cell ( Fig. 4A, B) .
A lack of AGX1 activity towards synthetic N-acetylglucosamine (GlcNAc) analogs has previously prompted the engineering of AGX1 to recognize the corresponding GlcNAc-1-phosphate analog as a substrate (40) . As WT-AGX1 accepts both GlcNAc-1-phosphate and GalNAc-1-phosphate as substrates, we investigated whether AGX1 mutants could biosynthesize UDP-GalNAc analogs 1, 15 2 and 3 from the corresponding GalNAc-1-phosphate analogs in the living cell. We mutated the gatekeeper residues F381 and F383 to Gly or Ala in FLAG-tagged AGX1 expression constructs (40) . GalNAc-1-phosphate analogs were delivered to stably transfected HEK293T cells by virtue of caged precursors 5, 6 and 7. UDP-sugar biosynthesis was then determined by high performance anion exchange chromatography with pulsed amperometric detection (HPAEC-PAD) of cell 20 lysates. Gly and Ala mutants of F383 efficiently biosynthesized bumped UDP-GalNAc analog 1, while neither F381 single mutants nor any F381/F383 double mutants produced 1 despite equal expression levels ( Fig. 4A) (40) . In contrast to linear alkyne 1, neither methylated alkynes (2 or 3)
were biosynthesized by engineered AGX1 F383A , hereby called mut-AGX1 ( Fig. 5B and fig. S4B ).
We thus concluded that bumped GalNAc-1-P(SATE)2 precursor 5 can be used in conjunction with mut-AGX1 to deliver UDP-GalNAc analog 1 to the living cell and establish a GalNAcT bumpand-hole system. and was repeated for compound 5 in HEK293T cells transiently transfected with AGX1 constructs, as well as stably transfected K-562 cells ( Fig. S4B and fig. S5 ). Insert: epimerization to 8 is suppressed in GALE-deficient K-562 cells expressing mut-AGX1 and fed with 5, but not cells carrying a control single guide (sg)RNA. A reference trace of compound 1 is shown. Data are of one representative out of two independent experiments.
In HPAEC-PAD chromatograms of cells biosynthesizing UDP-GalNAc analog 1, we consistently 5 found a satellite peak that eluted after 1 (arrowhead in figure 4B ). The epimerase GALE maintains a cytosolic equilibrium between UDP-GalNAc and UDP-GlcNAc and has been shown to also accept azide-containing analogs (38, 41) . We found that GALE epimerizes UDP-GalNAc analog 1 to the corresponding UDP-GlcNAc analog 8 ( Fig. 4A) : first, HPAEC-mass spectrometry confirmed that the satellite peak was caused by an isomer of UDP-GalNAc analog 1 with 328 m/z 10 [M-2H] 2-. Second, CRISPR-mediated GALE-KO in the K-562 background abrogated the satellite peak ( Fig. 4B and fig. S5 ). In contrast, epimerization was still observed in GALE-containing cells.
Alkyne-containing UDP-GlcNAc analog 8 might result in labeling of GlcNAc-containing glycans on the cell surface, such as N-linked glycans. We thus concluded that epimerization of 1 to 8 must be accounted for in glycoproteomics experiments, for example by enzymatic abrogation of cell 15 surface N-glycans during sample processing.
A glyosyltransferase bump-and-hole-system in living cells
With a GalNAcT bump-and-hole system and a method for cellular substrate delivery of 1 in hand, we set out to probe isoenzyme-dependent glycosylation in the living cell. We cloned FLAG-tagged WT-or mut-AGX1 under a constitutive promoter into an expression vector containing VSV-G-20 tagged WT or DM versions of GalNAcT-1 or T-2 under the control of a Dox-inducible promoter (Fig. 5A ). This setup allowed us to systematically assess any potential background protein labeling when UDP-GalNAc analog 1 could not be biosynthesized, or when 1 was biosynthesized but DM-GalNAcTs were absent. To preclude any labeling due to epimerization of 1 to UDP-GlcNAc analog 8, we first used GALE-KO K-562 cells for labeling. Cells were supplemented with GalNAc to compensate for the loss of UDP-GalNAc biosynthesis (Fig. S5A ). GalNAcT expression was induced ( Fig. S6A) , cells were fed with caged GalNAc-1-phosphate analog 5, and the cell surface was reacted with clickable Alexa488-picolyl azide in the presence of a non-membrane-permissive 5 Cu(I) complex (3, 42) . After gating for positive VSV-G signal, flow cytometry showed a more than 15-fold fluorescence increase when both DM-T-2 and substrate 1 were present over controls lacking either ( Fig. 5B and fig. S6B ). In GALE-containing cells, a more than 2-fold higher signal was still measured over control cells when a functional bump-and-hole system was present ( Fig.   S6C ). 10 In order to better visualize the scope of protein labeling by our bump-and-hole system, we reacted cell surfaces with a clickable version of the infrared dye CF680 to profile labeled cell surface glycoproteins by in-gel fluorescence. We compared protein labeling patterns of GALE-containing K-562 cells stably expressing T-1 or T-2 constructs. Here, N-linked glycans were removed by PNGase F treatment prior to analysis to reduce background fluorescence (Fig. S7A) . A profound 15 band pattern was observed when functional bump-and-hole pairs (5, mut-AGX1 and DM-GalNAcTs) were present ( Fig. 5C and fig. S7B ). Mut-AGX1 was required for labeling, confirming that our experiments probe enzymatic glycosylation rather than non-specific protein modification (43). Fluorescence was of similar intensity as in cells treated with well-characterized alkynecontaining N-acetylneuraminic acid precursor Ac4ManNAlk (44) . Furthermore, the presence of fig. 5E and fig. S9 ). Following an automated search for glycopeptides containing the GalNAc analog alone or as a part of longer glycans, we obtained raw glycopeptide hits which we manually validated. Seventy-seven spectra were found of DM-T-2-modified 15 glycopeptides that corresponded to 37 peptides with 27 glycosylation sites and the presence of up to four different glycan compositions per glycopeptide, the structures of which were inferred based on biosynthetic considerations (Data S1) (18). In contrast, four glycopepetides were found as modified by DM-T-1. Control cells fed with DMSO or containing WT GalNAcTs and fed with GalNAc-1-phosphate analog 5 showed no hits at all, or one (WT-T-2) and two (WT-T-1) 20 glycopeptides, respectively. Several known glycosylation sites in the SimpleCell glycoproteomics dataset by Schjoldager et al. were confirmed herein, and new sites were revealed (Data S1) (19).
For instance, we found hitherto unannotated T-2 glycosylation sites in the proteins ITIL2, AMBP, Complement C3 and C4, GPC3 and STC2, and Laminin subunit gamma-1, among others ( Fig. 5E and Data S1). T-2 is involved in lipid homeostasis and was found to glycosylate certain apolipoproteins, including ApoE at Thr307 and Ser308, in HepG2 cells (17, 21) . Both sites were confirmed herein and, additionally, found to be elaborated up to the trisaccharide Neu5Acα-Galβ-GalNAc-Ser/Thr or tetrasaccharide Neu5Acα-Galβ-(Neu5Acα)GalNAc-Ser/Thr structures (Data 5 S1) (18). Our data resolved ambiguity about O-glycosylation of apolipoprotein A-1 (ApoA1) in the peptide sequence 220-ATEHLSTLSEK-230 (21) : previous data showed that upon T-2-KO, glycosylation of Thr221, Thr226 and Ser228 is slightly increased, but the reason for this was elusive (21) . Our gain-of function approach revealed that DM-T-2 glycosylated Ser225 while DM-T-1 glycosylated Thr221, indicating that T-2-KO cells lose Ser225 glycosylation that is 10 compensated by increased glycosylation at the other sites. We attribute the smaller number of annotated glycopeptides in DM-T-1 cells versus DM-T-2 to the lower expression of T-1 versus T-2 GalNAcTs at 0.5 µg/mL Dox and/or the fact that T-1 glycosylates extracellular matrix proteins which may not be sufficiently soluble in conditioned media ( Fig. 3B and fig. S3A ). We repeated the experiment using DM-GalNAcTs and treatment with caged GalNAc-1-phosphate analog 5 only, and found similar results (Data S2). Such detailed analysis is facilitated by the gain-offunction chemical tagging strategy that emulates native GalNAcT activity as a result of our bumpand-hole approach.
Discussion
The cellular glycoproteome is subject to disease-related alterations. Yet, we still lack methodology 20 to selectively visualize, modify or sequence either a certain glycan subtype or the product of a certain GT. Bump-and-hole engineering has been artfully employed to obtain insight into the protein substrates of single kinases (4, 46) , ADP-ribosyltransferases (5, 6), and methyltransferases (37, 47, 48) , among others (9). Only few of these systems have been established in the living cell, as cellular delivery of bumped substrates is rarely straightforward, especially when substrates are nucleotide-based. Herein, we established the first GT bump-and-hole system in the living cell to profile GalNAcTs, the largest GT family in the human genome. The fascinating biology of GalNAcTs, with multiple isoenzymes and a profound cross-talk between glycosylation and 5 proteolysis (34, 49), prompted us to develop an isoenzyme-specific chemical reporter. This approach allowed us to expand our knowledge on T-1 and T-2 glycosylation sites by adding information on the nature of the mature glycans after extension by other GTs.
The era of quantitative biology demands great specificity in tools to probe cellular processes or expressed antigens. Biological tools, including antibodies, lectins, engineered binding proteins, or 10 silenced hydrolases have been employed to profile or isolate cellular glycans (45, 50) . While powerful probes, these proteins suffer from various drawbacks, including the dependence of binding on the structural context or the requirement to simplify glycans before performing binding studies. Additionally, all conventional strategies for glycan pull-down or visualization rely on postglycosylation derivatization or binding. As a consequence, information on GT isoenzyme 15 specificity is already lost orin the context of knock-out cell linesmay have been obscured by partial redundancy. This "specificity space" is covered by our bump-and-hole approach that enables GT-and glycosite-specific labeling. As GalNAcT engineering retains both threedimensional structure and peptide glycosylation preferences, this strategy probes glycosylation in an unbiased fashion without context dependence. Thereby, we obtained for the first time 20 information on both site and structure of glycans initiated by a single GT isoenzyme in a single experiment.
Taken together, we now have a strategy in hand to specifically modify GT isoenzyme-dependent glycosylation sites on the living cell. glycosylation. Bioorg. Med. Chem. 13, 5021-5034 (2005).
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A will be made available in a public repository.
Supplementary Materials:
Materials and Methods
Figures S1-S9 Table S1 15 Data S1 and S2 were analyzed by Western blot. Samples were re-blotted with a higher concentration of GALE antibody to assure absence of GALE in KO cells. Data are from one experiment. B, cells were fed with DMSO or compound 5, and UDP-sugar production was measured by HPAEC-PAD. GALE-KO contain elevated levels of UDP-Gal as cells are supplemented with galactose to maintain viability and UDP-Gal cannot be epimerized to UDP-Glc. Expression levels of AGX1 (FLAG) 10 and GALE are analyzed by Western blot. Data are of one representative out of two independent experiments. C, GALE-KO or control sgRNA-transduced K-562 cells stably transfected with the indicated AGX1 constructs were fed with the indicated compounds, and UDP-sugar production was measured by HPAEC-PAD. Data are from one experiment. figure 5C . The sialic acid precursor Ac4ManNAlk was used as a positive control, and the effect of omitting Dox was investigated. C, treatment of lysates prepared as in A with the glycoprotease StcE. Arrow indicates StcE band in Coomassie stain. D, dissecting GlcNAc vs. GalNAc labeling by using probes 5 and 9. GALE-KO K-562 cells expressing AGX1 and GalNAcT-2 constructs were treated with Dox or left untreated, and fed with compounds 5 or 9. 10 Labeling was performed as in figure 5C . Wild type K-562 cells prepared as in A were used to compare labeling patterns. Data are from one representative out of three independent experiments. 5 * Rmerge = Σhkl Σj=1 to N | Ihkl -Ihkl (j) | / Σhkl Σj=1 to N Ihkl (j), where N is the redundancy of the data. In parentheses, outermost shell statistics at these limiting values: 1.85 -1.80 Å in GalNac T2 with EA2 and UDP and 3.21 -3.05 Å in GalNac T2 UDP-GalNAc analog 1. † Rfactor = Σhkl ||Fobs| -|Fcalc|| / Σhkl |Fobs|, where the Fobs and Fcalc are the observed and calculated structure factor amplitudes of reflection hkl.
10 ‡ Rfree = is equal to Rfactor for a randomly selected 5.0 % subset of the total reflections that were held aside throughout refinement for cross-validation. § According to Procheck.
